In brief
On 3 February, the European Medicines Agency (EMA), the Heads of Medicines Agencies (HMA) and the European Commission launched a public consultation on the establishment of a multi-stakeholder platform to improve clinical trials in the European Union (“MSP“).
Key takeaways
The scope of the MSP is to bring together all the stakeholders in a neutral “forum”, including, by way of example, patient organizations, healthcare professionals, investigators, Clinical Research Organizations, Ethics Committees and regulators, in order to promote innovation and increase mutual trust and understanding, thus improving the EU clinical trials landscape for the benefit of all EU citizens.
The composition of the MSP will be agreed at the end of the public consultation, scheduled for 3 March 2023; the date by which stakeholders can provide their comments on the proposal and possibly express their interest in participating in the platform.
